ROCKAWAY, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that gammaCore™ Sapphire (nVNS) has been included in a long-term reimbursement policy launched by the National Institute for Health and Disability Insurance (RIZIV / INAMI) in Belgium. Effective October 1, 2025, the policy provides coverage for gammaCore Sapphire to treat patients with cluster headaches. This coverage is based on strong clinical ...

Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through innovative non-invasive bioelectronic technologies [2] - The company's leading prescription products include gammaCore, a non-invasive vagus nerve stimulation (nVNS) device, and Quell neurostimulator, both aimed at treating chronic pain syndromes [2] - Additionally, electroCore offers Truvaga products, which are handheld nVNS devices designed for personal use to promote general wellness and human performance [2] Upcoming Financial Results - electroCore will report its financial results for the second quarter ended June 30, 2025, after the market closes on August 6, 2025 [1] - Management will host a webinar at 4:30 PM EDT on the same day to review the financial results and address investor questions [1] - Investors can access the webinar through a provided registration link and dial-in details [1]